📰 Human Use News
Page 44 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
September 27, 2023
On September 19, 2023, the U.S. Food and Drug Administration (“FDA” or “the Agency”) published a draft guidance, Regulatory Considerations for Prescription Drug Use-Related Software...
September 26, 2023
UCB announces approval of RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in JapanJapanese Ministry of Health, Labour and Welfare (MHLW) approves two UCB treatments, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan), f...
September 25, 2023
Prestige Biologics, a contract development and manufacturing organization (CDMO), announced it has signed a non-binding MOU with Aurigene…
September 25, 2023
UCB announces approval of RYSTIGGO[®] and ZILBRYSQ[®] for the treatment of adult patients with generalized myasthenia gravis in Japan Japanese Ministry...
September 22, 2023
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease?; more than 147,000 breast cancer patients in Europe die annually from the disease?ORSERDU is the first
September 22, 2023
Pressroom: Hier finden Sie die gesammelten Presseaussendungen von Takeda
September 22, 2023
ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...
September 21, 2023
Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head...
September 21, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®Sep 19, 2023 6:15 AMEuropean Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC)U.S. FDA accepts Biologics License Ap...
September 21, 2023
Travere Therapeutics, Inc. announced topline two-year confirmatory secondary endpoint results from the Company?s pivotal head-to-head Phase 3 PROTECT Study of FILSPARI® in IgA nephropathy versus...